Nancy Bigley (Committee Chair), Julian Cambronero (Committee Member), Andrew Hsu (Other), Barbara Hull (Committee Member)
Master of Science (MS)
IgA nephropathy is one of the most common kidney diseases worldwide. Most IgA nephropathy patients will undergo a kidney transplant as a treatment. Treatment currently includes the use of immunosuppressants which are necessary to prevent graft rejection but present harmful side-effects when taken long-term. This review focuses on strategies which have the ability to promote tolerance of both donor and recipient cells within a transplant recipient. Such strategies allow development of mixed chimerism and thereby alleviate the need for long-term immunosuppressant usage in allograft recipients. These strategies could be applied to IgA nephropathy patients to allow kidney allograft acceptance without the use of long-term immunosuppressant usage. These strategies may prevent recurrence of IgA nephropathy in kidney grafts.
Department or Program
Microbiology and Immunology
Year Degree Awarded
Copyright 2011, all rights reserved. This open access ETD is published by Wright State University and OhioLINK.